Skip to main content
. 2016 Sep 15;11(9):e0162970. doi: 10.1371/journal.pone.0162970

Table 3. Cumulative effects of IGFBP-3 rs2854744, DISI, and BMI on breast cancer risk.

NO. a Total Premenopausal Postmenopausal
Cases (%) Controls (%) OR (95%CI)b Cases (%) Controls (%) OR (95%CI)c Cases (%) Controls (%) OR (95%CI)d
0 28(10.1) 36(13.0) 1.00 18(12.6) 20(10.7) 1.00 10(7.5) 16(17.8) 1.00
1 101(36.5) 140(50.5) 0.93(0.53–1.62) 57(39.9) 91(48.7) 0.70(0.34–1.43) 44(32.8) 49(54.4) 1.44(0.59–3.49)
2 116(41.9) 86(31.0) 1.73(0.98–3.06) 54(37.8) 66(35.3) 0.91(0.44–1.89) 62(46.3) 20(22.2) 4.96(1.94–12.66)
3 32(11.6) 15(5.4) 2.74(1.25–6.03) 14(9.8) 10(5.3) 1.56(0.56–4.36) 18(13.4) 5(5.6) 5.76(1.62–20.45)
P trend 0.015 0.489 <0.001

a: The number of exposure factors, defined as theIGFBP-3 rs2854744 AA genotype, DISI <9.85 mg/day, and BMI ≥24 kg/m2

b: adjusted for education, income, age at first pregnancy, parity, breast feeding, and energy-adjusted protein, fat and dietary fiber intake

c: adjusted for education, income, age at first pregnancy, parity, breast feeding, and energy-adjusted protein, fat, carbohydrate and dietary fiber intake

d: adjusted for education, income, age at first pregnancy, parity, breast feeding, and contraceptive use